Skip to main content
Premium Trial:

Request an Annual Quote

Coriell Teams with NIH on Stem Cell Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Coriell Institute for Medical Research today said that it is collaborating with the National Institutes of Health to make a new line of stem cells available to researchers.

The lines of induced pluripotent stem cells are available through the National Institutes of General Medical Sciences' Human Genetic Cell Repository at Coriell. The stem cells, made from skin or blood cells, were derived from individuals with Huntington's disease, juvenile onset diabetes, muscular dystrophy, spinal muscular atrophy, and severe combined immunodeficiency.

"The promise of stem cell research lies in its application in understanding the progression of human disease, to better target therapies to optimize our health outcomes, and to ultimately use stem cells therapeutically to cure disease and reverse injury," Coriell President and CEO Michael Christman said in a statement.

The NIGMS Human Genetic Cell Repository has been managed by Camden, NJ-based Coriell since 1972 and currently contains more than 10,500 cell lines, said Coriell.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more